334 related articles for article (PubMed ID: 9922042)
1. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Estey E; O'Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM
Leuk Lymphoma; 1998 Nov; 31(5-6):521-31. PubMed ID: 9922042
[TBL] [Abstract][Full Text] [Related]
2. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Beran M; Kantarjian H; O'Brien S; Koller C; al-Bitar M; Arbuck S; Pierce S; Moore M; Abbruzzese JL; Andreeff M; Keating M; Estey E
Blood; 1996 Oct; 88(7):2473-9. PubMed ID: 8839838
[TBL] [Abstract][Full Text] [Related]
3. Topotecan in the treatment of hematologic malignancies.
Beran M; Kantarjian H
Semin Hematol; 1998 Jul; 35(3 Suppl 4):26-31. PubMed ID: 9779879
[TBL] [Abstract][Full Text] [Related]
4. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Estey E; O'Brien S; Cortes J; Koller CA; Giles FJ; Kornblau S; Andreeff M; Vey N; Pierce SR; Hayes K; Wong GC; Keating M; Kantarjian H
J Clin Oncol; 1999 Sep; 17(9):2819-30. PubMed ID: 10561358
[TBL] [Abstract][Full Text] [Related]
5. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Kantarjian H
Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
[TBL] [Abstract][Full Text] [Related]
7. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Quintas-Cardama A; Kantarjian H; O'Brien S; Jabbour E; Giles F; Ravandi F; Faderl S; Pierce S; Shan J; Verstovsek S; Cortes J
Cancer; 2006 Oct; 107(7):1525-9. PubMed ID: 16955510
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Lübbert M; Wijermans P; Kunzmann R; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
Br J Haematol; 2001 Aug; 114(2):349-57. PubMed ID: 11529854
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F
Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575
[TBL] [Abstract][Full Text] [Related]
11. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
[TBL] [Abstract][Full Text] [Related]
13. Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndrome.
Park SJ; Kim DW; Kim HJ; Eom HS; Min CK; Lee JW; Min WS; Kim CC
Korean J Intern Med; 2000 Jul; 15(2):122-6. PubMed ID: 10992724
[TBL] [Abstract][Full Text] [Related]
14. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.
Vaena DA; Walker P; Pennington K; Stephens A; Stender MJ; Yiannoutsos CT; Young C; Stoner C; Cripe LD;
Leuk Res; 2004 Jan; 28(1):49-52. PubMed ID: 14630080
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
[TBL] [Abstract][Full Text] [Related]
17. New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids.
Estey EH
Leukemia; 1998 Sep; 12 Suppl 1():S13-5. PubMed ID: 9777888
[TBL] [Abstract][Full Text] [Related]
18. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
19. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Cortes J; Estey E; Beran M; O'Brien S; Giles F; Koller C; Keating M; Kantarjian H
Leuk Lymphoma; 2000 Feb; 36(5-6):479-84. PubMed ID: 10784392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]